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Abstract
Purpose The objective of this study was to identify the most
clinically relevant drug–drug interactions (DDIs) at risk of
affecting acenocoumarol safety in our tertiary care universi-
ty hospital, a 2,000 bed institution.
Methods We identified DDIs occurring with acenocoumarol
by combining two different sources of information: a 1-year
retrospective analysis of acenocoumarol prescriptions and
comedications from our Computerized Physician Order Entry
(CPOE) system (n = 2,439 hospitalizations) and a retrospec-
tive study of clinical pharmacology consultations involving
acenocoumarol over the past 14 years (1994–2007) (n = 407).
We classified these DDIs using an original risk-analysis meth-
od. A criticality index was calculated for each associated drug
by multiplying three scores based on mechanism of interac-
tion, involvement in a supratherapeutic international normal-
ized ratio (INR) (≥ 6) and involvement in a severe bleeding.
Results One hundred and twenty-six DDIs were identified
and weighted. Twenty-eight drugs had a criticality index ≥
20 and were therefore considered at high risk for interacting
with acenocoumarol by increasing its effect: 75% of these
drugs involved a pharmacokinetic mechanism and 14 % a
pharmacodynamic mechanism. An unknown mechanism of
interaction was involved in 11 % of drugs.
Conclusion Twenty-eight specific drugs were identified as
being at high risk for interacting with acenocoumarol in our
hospital using an original risk-analysis method. Most ana-
lyzed drugs interact with acenocoumarol via a pharmacoki-
netic mechanism. Actions such as the implementation of
alerts in our CPOE system should be specifically developed
for these drugs.
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Introduction
Oral anticoagulants, especially vitamin K antagonists (VKAs;
i.e. warfarin, phenprocoumone, acenocoumarol) are common-
ly prescribed and have proven to be highly effective in the
prevention and treatment of thromboembolic diseases [1].
Warfarin is the most widely used oral anticoagulant world-
wide, but this drug is not available in Switzerland where
acenocoumarol and phenprocoumone are the two registered
VKAs. Acenocoumarol is the VKA used in our institution.
Similar to other VKAs, acenocoumarol has a narrow
therapeutic index. It is mainly metabolized by cytochrome
P450 (CYP) 2C9 [2], but CYP1A2 and CYP2C19 also
participate in the biotransformation of acenocoumarol [3].
S-acenocoumarol is metabolized completely by CYP2C9,
whereas R-acenocoumarol is metabolized by CYP2C9
(50 %), CYP1A2 (30 %) and CYP2C19 (20 %). Unlike
warfarin, acenocoumarol is not metabolized by CYP3A4
[3].
Because of these characteristics, there is a large inter- and
intra-individual variation in dose response, and achieving a
safe and effective anticoagulation is a complex task [4].
Doses of acenocoumarol are therefore determined based
on the international normalized ratio (INR) response, with
a value of 2.0–3.0 being the target in most indications [5].
Although major bleeding can occur at a therapeutic level,
the risk of bleeding increases with increasing INR value [6].
Oral anticoagulants are frequently involved in adverse drug
reactions (ADRs), especially haemorrhage, and are in the
top ten drugs leading to hospital admissions due to ADRs
[7–10].
Numerous environmental and genetic factors (e.g. tobac-
co, weight, sex, age and single nucleotide polymorphisms)
influence the response to acenocoumarol treatment [5, 11].
Drug–drug interactions (DDIs) are an additional factor af-
fecting the variability of anticoagulation and the occurrence
of serious ADRs [4, 12–15]. These DDIs are well described
in the literature, but their respective importance in clinical
practice is difficult to determine, especially those involving
acenocoumarol since most of the studies published to date
have focused on warfarin. An additional limitation of the
literature on this topic is that many reports are based on case
studies, some of which are poorly documented [5].
According to several drug information compendia and
electronic systems, more than 200 different compounds
potentially interact with acenocoumarol [16–19]. Electronic
databases can be used (such as Lexi-Interact® or Epo-
crates®) to identify DDIs, either stand-alone or integrated
into a computerized physician order entry (CPOE) system.
The problem of such systems is “alert fatigue”, a phenom-
enon related to a high rate of irrelevant alerts leading physi-
cians to override them [20–22]. Moreover, in most of these
databases, warnings for acenocoumarol come from drug
interactions with warfarin. This situation is not problematic
for pharmacodynamic (PD) DDIs, but it can be problematic
for pharmacokinetic (PK) DDIs because acenocoumarol is
not metabolized by CYP3A4. Therefore, some DDIs alerts
are not adapted to acenocoumarol.
Prospective risk analysis approaches are used in a num-
ber of high hazard industries and could be applied more
systematically to health care [23, 24]. Among such methods,
“failure modes, effects and criticality analysis” (FMECA) is
a well-described tool that systematically assesses a given
process. FMECA is recommended both by Veterans Affairs
National Center for Patient Safety and the Institute for
Healthcare Improvement [25], and it is now being used in
health care to assess risk of failure and harm in processes as
well as to prioritize the most relevant areas for process
improvements [26–28]. FMECA has been used by hundreds
of hospitals in a variety of Institute for Healthcare Improve-
ment programs, including Idealized Design of Medication
Systems (IDMS), Patient Safety Collaboratives and Patient
Safety Summit. It identifies possible or likely errors (“fail-
ure modes”) and measures what their effect may be even
before they take place.
FMECA includes a quantitative evaluation of the criticality
of each failure mode. The criticality indexes are calculated by
multiplying three components: likelihood of occurrence,
severity and detection on the basis of known or estimated
data. Each failure mode is classified and the top critical events
subsequently determined. This process is a very helpful tool to
evaluate the acceptability of existing risks and to prioritize
actions to improve the safety of the patient [23].
The aim of this study was to identify which DDIs likely to
increase the effect of acenocoumarol could be implemented in
the CPOE system of our hospital setting (a 2,000 bed univer-
sity hospital). DDIs were also identified and then graded using
a method inspired by FMECA in the aim to focus on the most
clinically relevant DDIs.
Methods
Study population
Data were collected from adults treated with acenocoumarol
for different indications in a tertiary care hospital.
Data extraction
Firstly, retrospective data on acenocoumarol prescriptions
written between 1 May 2006 and 30 April 2007 were
anonymously extracted from all medical services of our
institution using the CPOE system (the services of surgery
and psychiatry did not have computerized prescriptions at
that time and were thus excluded). Information on doses,
618 Eur J Clin Pharmacol (2013) 69:617–627
treatment period, concomitant drugs and INR values was
extracted for every acenocoumarol prescription. A system-
atic interaction analysis between acenocoumarol and con-
comitant drugs was performed for every case in which an
INR of ≥6 was measured. This value was chosen to target
interactions because an INR of ≥6.0 is associated with a
significantly increased bleeding risk [29, 30]. All of the
interacting drugs the patient received, if more than one,
were regarded as being associated with the observed
supratherapeutic INR. A systematic interaction analysis
was also performed when blood products were administered
during the acenocoumarol treatment because this treatment
was considered to be a bleeding indicator.
Secondly, data extracted from the CPOE were sup-
plemented by a retrospective analysis of consultations
from the Division of Clinical Pharmacology and Toxi-
cology (one of the six Swiss Regional Pharmacovigi-
lance Centres). The aim of these consultations is to
prevent or identify and evaluate reports of ADRs and
therapeutic accidents. These consultations are electroni-
cally archived in an Access® application from which
data were extracted from 1994 to the end of 2007. We
analysed each consultation involving acenocoumarol
which was requested from physicians working in our
institution. From these data, we extracted co-medication
(s) linked with a fluctuating INR, subtherapeutic INR
and supratherapeutic INR and/or bleeding complications
by patients treated with acenocoumarol.
Identification of clinically relevant DDIs
The potential of drugs to interact clinically with acenocou-
marol in the University Hospitals of Geneva (HUG) was
estimated by combining three different sources of informa-
tion: the table of PK interactions developed by the Division
of Clinical Pharmacology and Toxicology [31] and two
online DDI detection systems: the online version of Lexi-
Interact™ [17] and the online version of Theriaque®, a
French database [32]. DDIs identified in our study were
present in at least one of the three sources consulted.
All medications identified as having a potential to inter-
act with acenocoumarol were classified by their mechanism
of action as PK, PD or unknown.
Weighting of the clinically relevant DDIs
In order to focus on the most relevant DDIs liable to potenti-
alize the effect of acenocoumarol and to add these as a
warning in our CPOE, we weighted DDIs identified in the
two retrospective studies using an original risk-analysis
method based on the FMECA method. A criticality index
was calculated for each associated drug by multiplying three
scores.
The first score was based on the mechanism of the
interaction and varyied from 1 to 10 depending on the exact
mechanism involved (Table 1). Drugs that interact with
acenocoumarol through a PK mechanism were classified
as strong or weak inhibitors of CYP2C9, CYP2C19 and
CYP1A2, based on the classification found in the table of
PK interactions developed by the Division of Clinical Phar-
macology and Toxicology [31]. The distinction between
strong and weak inhibitor was defined based on the disso-
ciation constant for inhibitor binding (KI) of the drugs.
These constants were determined through in vitro studies
or from in vivo studies, when available. Because CYP2C9 is
the major metabolic pathway of acenocoumarol, the highest
rank of 10 was attributed to drugs known to strongly inhibit
Table 1 Weighting score according to the mechanism of the interac-
tion, the frequency of involvement in a supratherapeutic INR and the
frequency of involvement in a bleeding event
Weighting scores Ranking
Mechanism of the interaction
Pharmacokinetic
Strong inhibitor of CYP2C9 10
Weak inhibitor of CYP2C9 8
Strong inhibitor of CYP2C19 5
Strong inhibitor of CYP1A2 5
Weak inhibitor of CYP2C19 3
Weak inhibitor of CYP1A2 3
Pharmacodynamic
Strong pharmacodynamic interaction (antiaggregant
effect)
10
Moderate pharmacodynamic interaction (SSRIs) 8
Unknown mechanism 1
Frequency of involvement in a supratherapeutic INR (INR ≥6)
0 1
1–10 2
11–20 3
21–30 4
31–40 5
41–50 6
51–60 7
61–70 8
71–80 9
> 80 10
Frequency of involvement in a bleeding event
0 1
1 4
2–3 6
4–5 8
6 10
INR, International normalized ratio; CYP, cytochrome P450; SSRIs,
selective serotonin reuptake inhibitors
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this cytochrome. A rank of 8 was attributed to weak inhib-
itors of CYP2C9. Given that CYP1A2 and CYP2C19 are
minor metabolic pathways, the rank of 5 was assigned to
strong inhibitors of these cytochromes and a rank of 3 to
weak inhibitors. In terms of PD interactions, we gave the
highest score of 10 to drugs used for their antiaggregant
effect because there is a clear PD interaction between these
drugs and VKAs [e.g. antiaggregant drugs and non-steroidal
anti-inflammatory drugs (NSAIDs)] and a score of 8 to
drugs interacting with VKAs through a PD mechanism but
not as strongly documented as for antiaggregant drugs and
NSAIDs. This latter category of drugs was essentially rep-
resented by selective serotonin reuptake inhibitors (SSRIs).
When a drug interacted with acenocoumarol through both a
PK and a PD mechanism, the highest rank was chosen. For
example, the designated rank of clopidogrel is 8 based on its
PK mechanism (weak CYP2C9 inhibitor) and 10 based on
its PD mechanism (antiaggregant). The rank chosen for
clopidogrel is therefore 10 (the highest rank of both). When
a drug inhibited more than one CYP enzyme the highest
ranking was also attributed. For example, fluconazole is a
strong CYP2C9 and CYP2C19 inhibitor. The rank of this
drug is therefore 10 due to its inhibitory effect on CYP2C9.
The second score depended on the frequency at which the
drug was involved in a supratherapeutic INR (INR ≥6) and
ranged from 1 to 10 (Table 1).
The third score depended on the frequency at which the
drug was involved in a bleeding episode (Table 1). As
proposed by the FMECA method, the criticality index was
obtained by multiplying these three scores together. Based
on these scores, we established a classification from the
most to the less critical association.
Results
Identification of clinically relevant DDIs
Analysis of the data extracted from the CPOE system
There were a total of 61,814 hospitalizations during the
study period, of which 2,439 (4 %) involved an acenocou-
marol prescription, representing a total of 43,785 doses. The
mean age of the study population was 74.2 years [95 %
confidence interval (CI) 73.68–74.76], and 49 % of the
patients were female.
A total of 957 different drugs were co-prescribed 214,131
times with acenocoumarol. Heparin and enoxaparin, the
low-molecular-weight heparin of choice in our institution,
were not taken into account because these drugs are pre-
scribed in many indications in combination with VKA until
the anticoagulant effect of the latter is reached (e.g. in case
of deep vein thrombosis). Based on the three different
sources for DDI detection described in the previous section,
154 of the 957 co-prescribed drugs were identified as having
a potential interaction with acenocoumarol. These 154 drugs
were prescribed 46,642 times with acenocoumarol, repre-
senting 22 % of all co-medications. The top ten drugs
potentially interacting with acenocoumarol, were paraceta-
mol (n011,335), acetylsalicylic acid (ASA) (n03,799),
prednisone (n03,382), tramadol (n02,986), ceftriaxone
(n01,785), amlodipine (n01,725), clopidogrel (n01,549),
pravastatin (n01,099), ciprofloxacin (n01,042) and amio-
darone (n0963). Of the potential DDIs met with acenocou-
marol, 22 % were PK interactions, 14 % were PD
interactions, 9 % were associated with both mechanisms
and 56 % of the remaining potential interactions had a
mechanism of action not yet clearly understood.
In order to identify clinically significant DDIs with ace-
nocoumarol more accurately, we analysed hospitalizations
with INRs of ≥6, leading to the identification of 318 supra-
therapeutic INRs of which 89 % (n0283) of these cases had
at least one potential DDI. Seventy-four different drugs were
involved in these supratherapeutic INRs. For PK interac-
tions, 29 different drugs interacted with acenocoumarol; in
97 % of the cases, drugs were represented by inhibitors of
CYP2C9, CYP2C19 and/or CYP1A2. Amiodarone, val-
proate and azole antifungal drugs (econazole, fluconazole)
represented the majority of these inhibitors. Eight different
drugs had a PD mechanism of interaction with acenocou-
marol, with ASA being the most predominant (78 %). Six
drugs were classified has having both a PD and a PK mech-
anism of interaction, namely, SSRIs (49 %), clopidogrel
(46 %) and ibuprofen (5 %). Thirty-one drugs (42 %) were
classified has having an interaction with acenocoumarol that
has not yet been clearly explained; this group was mainly
represented by antibiotics (37 %), paracetamol (21 %), corti-
costeroids (13 %), statins (12 %) and levothyroxine (6 %).
Seven hospitalizations required the administration of
blood products, such as fresh frozen plasma. Based on the
fact that such products are administered in cases of major
bleeding, drugs interacting with acenocoumarol at the time
of bleeding were identified. A total of 17 different drugs
were identified: ASA, amiodarone, bosentan, cefepim, cef-
triaxone, ciprofloxacin, clarithromycin, clopidogrel, esome-
prazole, fluvastatin, leflunomide, paracetamol, phenytoin,
pravastatin, prednisone, the hydrochlorothiazide/irbesartan
association and the imipenem/cilastatin association.
Clinical pharmacology consultations
Analysis of the clinical pharmacology consultations showed
that acenocoumarol appeared in 407 consultations (3 %)
among a total of 13,560 consultations and that for 225
(55 %) of these consultations the reason for the request was
to determine if there was a DDI problem in the patient’s
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treatment either before or after the treating physician encoun-
tered difficulty in managing the INR. In 74 % of these 225
consultations (n0166), at least one clinically significant DDI
was present, involving 114 different drugs. Three quarters of
these drugs (n082) shared the same metabolic pathway and
interactedwith acenocoumarol through a PKmechanism, with
60 % represented by substrates, inhibitors or inducers of
CYP2C9, CYP2C19 or CYP1A2.
Drugs involved in PD interactions (n032, 28 %) were
essentially represented by antiplatelet drugs (e.g. ASA).
Of the 225 consultations requested, 52 % (n0117)
concerned a difficulty in adjusting the INR, with 49% relating
to a supratherapeutic INR, 34 % to a subtherapeutic INR and
17% to a fluctuating INR. At least one clinically relevant DDI
with acenocoumarol was identified in 96 % of the consulta-
tions for a supratherapeutic INR, 55% of the consultations for
a subtherapeutic INR and 70 % of the consultations for a
fluctuant INR. Drugs interacting most frequently with aceno-
coumarol in these three categories are reported in Table 2.
Physicians spontaneously reported 17 cases of bleeding
associated with acenocoumarol to the pharmacovigilance
centre. In 88 % of these reports, a clinically relevant DDI
with acenocoumarol was observed, due most often to amio-
darone, clopidogrel and ASA.
Weighting of clinically relevant DDIs
A total of 126 drugs were weighted, including the 74 drugs
implicated in an INR of≥6 and the 114 drugs identified in
the consultations of clinical pharmacology. Given that there
were duplicates, the total number of drugs is 126 and not
188. Each drug identified was weighted and a criticality
index was determined. The highest criticality index value
was 640 and the lowest 1 (Table 3).
For example, the criticality index of amiodarone was 640
based on the multiplication of the three scores defined below:
Table 2 Drugs interacting with
acenocoumarol in clinical phar-
macology consultations for dif-
ficulty in adjusting the INR
n, Number of observations
Supratherapeutic INR (n091) (%) Fluctuation of INR (n021) (%) Subtherapeutic INR (n027) (%)
Amiodarone (11) Fluconazole (14) Carbamazepine (15)
Acetaminophen (7) Amiodarone (10) Phenytoin (7)
Acetylsalicylic acid (5) Others (76) Rifampicin (7)
Clopidogrel (5) Others (71)
Esomeprazole (4)
Simvastatin (4)
Amoxicillin (3)
Clavulanic acid (2)
Ceftriaxione (2)
Fluconazole (2)
Voriconazole (2)
Others (53)
Table 3 Drugs with a
criticality index of ≥20 INN (International
Non-proprietary
Name)
Criticality
index
1 Amiodarone 640
2 Acetylsalicylic acid 600
3 Esomeprazole 400
4 Clopidogrel 240
5 Paracetamol 80
6 Fluvastatin 80
7 Celecoxib 80
8 Fluvoxamine 64
9 Leflunomide 64
10 Ciprofloxacin 60
11 Escitalopram 40
12 Diclofenac 40
13 Omeprazole 40
14 Metronidazole 30
15 Clarithromycin 24
16 Simvastatin 24
17 Econazole 24
18 Prednisone 20
19 Fluconazole 20
20 Valproic acid 20
21 Ibuprofen 20
22 Lysine
acetylsalicylate
20
23 Imatinib 20
24 Miconazole 20
25 Pantoprazole 20
26 Voriconazole 20
27 Etodolac 20
28 Ketorolac 20
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– Score for the mechanism of the interaction was 10,
because amiodarone is a strong inhibitor of CYP2C9
(Table 1).
– Score for the association with a supratherapeutic INR
was 8 (because amiodarone was involved more than 60
times in a supratherapeutic INR) (Table 1).
– Score for the association in a bleeding was 8 (because
amiodarone was associated 4 times in a bleeding epi-
sode) (Table 1).
To target the most relevant DDIs and limit the number of
alerts to implement in our CPOE, we considered drugs with
a criticality index of ≥20, a number which we set arbitrarily,
to be at the highest risk of interacting with acenocoumarol.
Among the drugs tested, 28 had a criticality index of≥20
(Table 3). These drugs are essentially represented by five
therapeutic classes: NSAIDs, proton pump inhibitors (PPIs),
antibiotics, SSRIs and statins. When classified according to
their mechanism of interaction, 75 % of the drugs had a PK
mechanism of interaction with acenocoumarol (in some
cases with an additional PD mechanism), 14 % a PD mech-
anism of interaction and 11 % had a mechanism of interac-
tion that is not clearly explained (Table 4).
Discussion
Using specific data on the prescribing habits of the physicians
in our institution, we were able to apply the original risk-
analysis method described here to identify 28 frequently used
drugs which had a very high risk to clinically interact with
acenocoumarol; these fall into the group of the 200 drugs
reported in the literature as potentially interacting with
acenocoumarol. The results obtained are specific to acenocou-
marol and are not derived from data collected with warfarin.
These DDIs should be clearly identified in our CPOE system.
About two-thirds of these drugs were found to interact
with acenocoumarol through a PK mechanism by inhibiting
the CYPs responsible for acenocoumarol’s biotransforma-
tion. Based on our weighting method, amiodarone, PPIs,
statins, quinolones and azole antifungal drugs are involved
in the highest proportion of these DDIs.
The drug at highest risk to clinically interact with aceno-
coumarol is amiodarone (criticality index 0 640), a strong
inhibitor of CYP2C9. This interaction has been identified
years ago (first report 1988) and is well described in the
literature (especially for warfarin) [19, 33, 34]. A close
monitoring is recommended when this drug is administered
with acenocoumarol, and given the long half-life of amio-
darone, caution should also be taken several weeks after the
treatment has been interrupted.
Esomeprazole also appears to have a high risk of inter-
acting with acenocoumarol (criticality index0400). This
isomer of omeprazole is the most prescribed PPI in our
institution. PPIs are frequently associated with VKAs as a
means to reduce the risk of gastro-intestinal bleeding. PPIs
(esomeprazole, omeprazole, pantoprazole) are potent inhib-
itors of CYP2C19 and for this reason the prescribing of PPIs
with a VKA is associated with a warning in most of the
databases used to detect DDIs. For example, in the Lexi-
comp Online, the association of acenocoumarol and esome-
prazole is summarized by the following information
“Esomeprazole may increase the serum concentration of
Vitamin K Antagonists”, and it is recommended that the
response to warfarin or acenocoumarol be monitored closely
when used together with esomeprazole [35]. Our results are
Table 4 Mechanism of interac-
tion for the 28 drugs identified at
highest risk to interact with ace-
nocoumarol (Criticality index ≥
20)
PK, Pharmacokinetic; PD,
pharmacodynamic
PK mechanism PD mechanism PK and PD mechanism Unknown mechanism
Amiodarone Etodolac Celecoxib Clarithromycin
Esomeprazole Ketorolac Fluvoxamine Prednisone
Fluvastatin Acetylsalicylic acid Ibuprofen Paracetamol
Ciprofloxacin Lysine acetylsalicylate Clopidogrel
Omeprazole Escitalopram
Metronidazole Diclofenac
Simvastatin
Econazole
Fluconazole
Valproate
Imatinib
Leflunomid
Miconazole
Pantoprazole
Voriconazole
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similar with those published by Holbrook et al. [34] who
classified omeprazole in the category of drugs with a level
of causation of interaction “highly probable” in a review on
warfarin and its drug interactions. However, the effect of
PPIs on coumarin remains controversial. In a recent study,
omeprazole significantly increased the area under curve
(AUC) and half-life of R-warfarin in homozygous extensive
metabolizers of CYP2C19 to levels comparable to those in
poor metabolizers; however, no clinical consequence was
observed [36]. To the best of our knowledge, no specific data
on the interaction between PPIs and acenocoumarol are avail-
able. In a recent in vitro study, esomeprazole and omeprazole
were considered as irreversible CYP2C19 inhibitors [37].
Moreover, in a crossover clinical study, a significant DDI
was observed between high doses of omeprazole and clopi-
dogrel in healthy subjects [38]. Considering the contribution of
CYP2C19 in the metabolism of R-acenocoumarol (the isomer
mainly responsible for the effect of acenocoumarol) and given
the short half-life of PPIs (approximately 1 h) and controversial
data, we consider that PPIs can be prescribed safely if the drug
is not taken at the same time as acenocoumarol.
Two statins, simvastatin and fluvastatin, are in the category
of clinically significant PK interactions. According to Hol-
brook et al., interaction between these two statins and warfarin
can be considered to be clinically significant and the level of
causation defined as “probable” [34]. The mechanism of
interaction has not been established for all statins, but some
statins clearly interact with VKAs by inhibiting CYP2C9 (e.g.
fluvastatin). Simvastatin does not seem to have a major effect
on CYP2C9, but an increased effect of warfarin or acenocou-
marol in the presence of simvastatin has been observed in
small retrospective studies and some case reports [39]. It was
also observed that the average dose of warfarin in patients on
simvastatin was reduced by 12 %. In the case of simvastatin,
which binds to plasma proteins, a shift of plasma protein
binding could explain the interaction [40].
Azole antifungal drugs appear also at high risk to clinically
interact according to a PK mechanism with acenocoumarol.
These DDIs are frequently reported and well described (inhi-
bition of CYP2C9 and CYP2C19) [19, 34, 41].
Drugs which fell in the mixed PK and PD mechanisms
category are the SSRIs (fluvoxamine, escitalopram),
NSAIDs and clopidogrel. They are metabolized by or are
inhibitors of CYPs involved in the acenocoumarol metabo-
lism and also impact on the PD effects.
In the study of Holbrook et al. [34], the interaction between
SSRIs (most particularly citalopram) and warfarin is classified
as being clinically significant and the level of causation de-
fined as “highly probable” [34]. Some SSRIs are metabolized
by the same isoenzymes as oral anticoagulants. For example,
fluvoxamine, an inhibitor of CYP1A2 and CYP2C9, appears
to be the most likely SSRI to interact with warfarin [42, 43].
Pharmacodynamically, SSRIs could interact with
acenocoumarol since the release of serotonin by platelets
plays an important role in haemostasis [44, 45]. This mecha-
nism has not been clearly explained, but recent epidemiolog-
ical data have demonstrated that SSRIs could significantly
increase the risk of gastro-intestinal bleeding [46, 47]. Accord-
ing to some studies, the use of SSRIs among the population
treated with coumarins seems to place patients at an increased
risk of bleeding [15, 48, 49]. A warning should be added to
make the physician aware of this interaction.
DDIs between NSAIDs, including COX-2 inhibitors, and
oral anticoagulants are clearly documented in the literature
and are frequently highlighted in studies on interactions and
oral anticoagulants [12, 41].
Our results suggest that the interaction between clopidog-
rel and acenocoumarol is important and can be considered
as clinically significant through a PK and a PD mechanism.
Clopidogrel inhibits CYP2C9 and has an antiaggregant ef-
fect. In the literature, data on this interaction are contradic-
tory and limited. Clopidogrel is not mentioned in a literature
review of interactions occurring with warfarin [34], but
prescribing information provided by Swiss manufacturers
clearly states that when prescribed with a VKA, clopidogrel
may be associated with a significant increased risk of bleed-
ing [50]. In addition, the association of clopidogrel, aspirin
and warfarin significantly increase the risk of gastro-
intestinal bleeding [51]. In a recent study, the risk of bleed-
ing was significantly increased when clopidogrel was co-
prescribed with warfarin [adjusted relative risk (AdjRR)
2.23, 95 % CI 1.48–3.36] in the elderly population [52].
In our study, three drugs, namely, paracetamol, predni-
sone and clarithromycin, represent most of the interactions
that do not have a clearly explained mechanism.
Paracetamol is the analgesic of choice for patients using oral
anticoagulants because this drug is justifiably considered to be
safer than NSAIDs. Small prospective studies of various
designs and case studies describe aberrant INR results in
patients using paracetamol while concomitantly receiving war-
farin. These INR elevations typically involved the ingestion of
at least 2 g/day of paracetamol for several consecutive days
[53]. In our study, paracetamol appears to be clinically inter-
acting with acenocoumarol. This result can be explained by the
fact that the association of these two drugs is characterized by a
warning in the DDI databases consulted in our study. For
example, Lexicomp Online contains the warning that patients
taking paracetamol at higher doses and/or for longer duration
may be at greater risk for experiencing a clinically significant
interaction [54]. In our study, paracetamol was frequently
associated with supratherapeutic INR. For this reason, this
drug was identified as a potential clinical DDI when prescribed
with acenocoumarol. Given that paracetamol is the analgesic
of choice during VKA treatment and based on data reported in
the literature data, this association should be represented by a
warning only with paracetamol doses of >2 g/day.
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Our results suggest that clarithromycin is a drug with a
high risk of interacting with acenocoumarol in our institu-
tion. This drug has previously been reported as probably
interacting with warfarin [34]. This interaction with warfarin
is partially explained through a PK mechanism because
clarithromycin is an inhibitor of CYP3A4 [55]. However,
this is not the case with acenocoumarol because it is not
metabolized by CYP3A4. Although the mechanism of this
DDI is not well established, it is known that many anti-
biotics interact with VKAs [56].
The interaction of prednisone with VKAs is reported in
the Lexicomp Online, and the severity of this DDI is clas-
sified as major. The mechanism by which corticosteroid use
is associated with an increase in INR and decrease in war-
farin dose requirements is not clear [57]. The prescribing
information provided by Swiss manufacturers states that
prednisone may decrease or increase the anticoagulant effect
of the oral anticoagulant [50].
Interactions with an oral anticoagulant, especially with
warfarin, are well described in the literature, but “real-life”
data on the actual occurrence of such interactions are scarce.
CPOE systems are valuable databases that can be used to
study “real-life” conditions. Few studies have analysed the
frequency and type of potential drug interactions during
anticoagulant therapy with VKAs using CPOE systems.
Moreover, the majority of these studies have analysed DDIs
with warfarin because this drug is the VKA of choice in
many countries [41]. Although PD interactions are identical
for warfarin and acenocoumarol, this is not the case for all
PK interactions as acenocoumarol, unlike warfarin, is not
metabolized by CYP3A4 [3].
A retrospective cohort study (1991–2003) that included
phenprocoumone and acenocoumarol users in the Nether-
lands (n076,455) demonstrated that potential DDIs occur
frequently in daily practice, with two-thirds of patients
being confronted with an increased risk of bleeding.
NSAIDs and antibacterial drugs were the most frequently
interacting drugs. In this study, 24 individual drugs and 11
drug groups interacting with VKAs according to the central
database used in Dutch pharmacies were taken into account
[12]. The same authors, using the same methodology, but
including new users of phenprocoumone or acenocoumarol,
subsequently identified the main comedications associated
with major bleeding episodes during anticoagulant therapy
as antibacterial drugs, NSAIDs, antithrombotic drugs and
tramadol [58]. In a study based on the Norwegian sponta-
neous reporting system, data on warfarin-associated bleed-
ing events (n0289) as a consequence of drug interaction
were detected in more than 50 % of the cases involving
antibacterials, NSAIDs/COX-2 inhibitors and heparins [59].
These results are also in accordance with our study.
Snaith et al. used the computerized prescribing data retriev-
er from primary care practices in Scotland to investigate the
prevalence of prescriptions that might rise the risk of clinically
relevant DDIs in a warfarinized population (n017,861) [41].
NSAIDs, antibacterials and antithrombotics were the most
frequently prescribed drug groups with a potential for DDIs.
Another study investigated the frequency and clinical conse-
quences of warfarin drug interactions using medical records of
6,772 warfarin-treated patients hospitalized in Finland (1996–
2004). In this study, 48 % of patients were exposed to inter-
acting co-medications. The adjusted odds ratio (OR) for
bleeding was highest for CYP2C9 inhibitors (OR 3.6, 95 %
CI 2.4–5.6), while NSAIDs, coxibs and SSRIs were also
associated with a significant bleeding risk (OR 2.6, 95 % CI
1.6–4.2; OR 3.1, 95 % CI 1.4–6.7; OR 2.6, 95 % CI 1.5–4.3,
respectively). The OR for the platelet aggregation inhibitor
group was 1.6 (95 % CI 0.8–3.1) [15].
A recent cohort study using a health insurance claims
database showed that 80 % of atrial fibrillation patients were
receiving at least one warfarin-potentiating medication while
taking warfarin. Patients who used these medications had a
26 % higher risk of haemorrhage than those who did not use
these drugs. The likelihood of haemorrhagic events was sig-
nificantly increased with the use of potentiating drugs from
the following therapeutic classes: anticoagulants (OR1.91),
anti-infectives (OR1.76), antiplatelets (OR1.56) and analge-
sics (OR1.33) [60]. In another recent retrospective study in an
elderly population (n017,600) who used warfarin, bleeding-
related hospitalization rates were significantly increased when
warfarin was co-prescribed with aspirin (AdjRR 1.44, 95 %
CI 1.00–2.07), clopidogrel (AdjRR 2.23, 95 % CI 1.48–3.36),
clopidogrel with aspirin (AdjRR 3.44, 95 % CI 1.28–9.23),
amiodarone (AdjRR 3.33, 95 % CI 1.38–8.00) and antibiotics
(AdjRR 2.34, 95 % CI 1.55–3.54) [52]. The majority of the
drugs identified through these studies are identical to those
identified in our study.
Various studies recommend reducing alert fatigue by low-
ering the number of alerts being sent to the clinician and by
increasing alert specificity [61, 62], but the identification of
high-priority DDIs for use in electronic health records is still
the subject of ongoing debate and can differ from one institu-
tion to another [63]. The major advantage of our method,
which is adapted from the FMECA, lies in its simplicity and
the quantitative evaluation it allows by combining three com-
plementary factors based on pharmacological characteristics
and clinical effects of drugs. This method helped us to identify
the most critical DDIs with acenocoumarol in order to specif-
ically develop computerized clinical decision support for these
high-risk associations. This method could be applied in other
institutions equipped with a CPOE in order to customize and
focus on “high risk” DDI alerts. Most of the DDIs identified
were due to a PK mechanism. We are of the opinion that it is
important to add these DDIs as a warning in our CPOE
because it is difficult to memorize which cytochrome is re-
sponsible for the metabolism of a specific drug. Awarning for
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the need for close monitoring through more frequent INR
controls should be advised when such a drug is introduced
or stopped by a patient treated by acenocoumarol. The results
of our study also indicated that for the PD interactions iden-
tified in our study, a warning should be added. This kind of
DDIs is difficult to manage because the risk of bleeding is
continuous over time and can not be determined through the
INR value. These drugs should be avoided in combination
with acenocoumarol unless proven to provide benefit that
outweighs the risk of bleeding.
There are some limitations to our study that should be
considered. First, it is a retrospective study, and some data
were not available, such as patient characteristics, comorbid-
ities, length of therapy. Similar to DDIs, these data may be
involved in the risk of overanticoagulation. As patients may
receive different potentially interacting drugs, the association
is not always clear, and more detailed data on each patient
would have allowed us to clarify some of the drug associa-
tions, such as those for the prescription of esomeprazole and
paracetamol. Secondly, despite the fact that pharmacological
and clinical parameters (INR elevation and bleeding events)
were considered to be the mechanism of the interaction, the
final score of 20 for the criticality index was chosen arbitrarily.
The method we adopted did not allow us to determine the
criticality index for drugs at risk to decrease the effect of
acenocoumarol because the score was focused on suprather-
apeutic INRs and bleeding episodes.
Conclusion
In this study, we targeted drugs at high risk to interact
clinically with acenocoumarol based on our analysis of the
prescribing data from the computerized physician order entry
system of our institution. The drugs interacting phamacokineti-
cally with acenocoumarol represent the major part of the DDIs
identified. To improve the safety of acenocoumarol prescrip-
tion in our institution, actions such as implemented alerts for
these drugs in our computerized physician order entry system
should be prioritized. This method can be applied to other
drugs known to be subject to many drug interactions.
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